Enterome to present three abstracts on its novel OncoMimics™ cancer immunotherapies at ASCO 2022

Enterome to present three abstracts on its novel OncoMimics™ cancer immunotherapies at ASCO 2022

World first clinical data of EO2401, Enterome’s first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, to be presented

Paris, France – May 27, 2022

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announced the publication of three abstracts related to its OncoMimcs™ pipeline, including EO2401, its first-in-class off-the-shelf OncoMimics™  cancer immunotherapy, ahead of poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually.

Enterome will present clinical proof-of-concept data from its most advanced OncoMimics™ drug candidate, EO2401, a therapeutic cancer vaccine candidate currently in clinical development for the treatment of patients with first progression/recurrence of glioblastoma (ROSALIE trial, EOGBM1-18) and for the treatment of patients with locally advanced or metastatic adrenocortical carcinoma, or malignant pheochromocytoma/paraganglioma (SPENCER trial, EOADR1-19).

A third poster describing the Phase 1/2 trial (SIDNEY, EONHL1-20) with Enterome’s second OncoMimics™ vaccine, EO2463, in non-Hodgkin lymphoma will also be presented at ASCO.

Details of the poster presentations and session are as follows:

ROSALIE Trial (EOGBM1-18)

• Title: EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma
• Track: Central Nervous System Tumors
• Abstract number: #2034
• Date and Time: Sunday, June 5, 8:00 AM-11:00 AM CDT
• Presenter: Professor Wolfgang Wick, Universitätsklinikum Heidelberg and German Cancer Research Center, Heidelberg, Germany
• Authors: Wick, W. et al

SPENCER Trial (EOADR1-19)

• Title: EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC)
• Track: Genitourinary Cancer—Kidney and Bladder
• Abstract number: #4596
• Date and Time: Saturday, June 4, 1:15 PM-4:15 PM CDT
• Presenter: Professor Vivek Subbiah, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX
• Authors: Baudin, E. et al

SIDNEY Trial (EONHL1-20)

• Title: A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma
• Poster session: Hematologic Malignancies/Lymphoma and Chronic Lymphocytic Leukemia
• Poster number: #TPS7586
• Date and Time: Saturday, June 4, 8:00 -11:00 AM CDT
• Authors: Zinzani, P.L et al

More information on the ASCO 2022 Annual Meeting and related poster presentations can be found at www.asco.org